Physician profile
Salman Ashfaq
NPI 1912985052
$7,787.90
in general payments reported to CMS, 2019-2025
45 companies · $1,063 in 2025
The $1,063 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $433 · 2021: $1,267 · 2022: $1,005 · 2023: $1,099 · 2024: $1,053 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.41 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,135.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $739.72 | 2019-2025 | |
| Amgen INC. | $693.89 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $522.62 | 2019-2025 | |
| Boston Scientific Corporation | $477.75 | 2022-2025 | Watchman Flx, Watchman Access System, Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $414.05 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $407.54 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $390.32 | 2019-2022 | |
| Abbott Laboratories | $296.68 | 2021 | |
| Amarin Pharma, INC. | $251.02 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.80 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $208.59 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $195.02 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.58 | 2019-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $126.71 | 2023-2024 | Inpefa |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Ashfaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.